Return on Equity (ROE): 23.41%
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 23.41% is in line with its 5-year average of 21.79%, near the high end of its 5-year range (16.44%–24.90%).
As of Friday, June 26, 2026. 5.31% above its 12-month average of 22.23%.
RMD Return on Equity (ROE) Chart
Annual fiscal-year return on equity; no daily interpolation.
RMD Average Return on Equity (ROE) Chart
RMD Current vs Average Return on Equity (ROE) Chart
RMD Return on Equity (ROE) Metrics
RETURN ON EQUITY (ROE)
23.41%
RETURN ON EQUITY (ROE) AVG TTM
22.23%
RETURN ON EQUITY (ROE) AVG 3Y
22.34%
RETURN ON EQUITY (ROE) AVG 5Y
21.79%
RETURN ON EQUITY (ROE) AVG 10Y
20.55%
RETURN ON EQUITY (ROE) AVG 15Y
19.28%
RETURN ON EQUITY (ROE) AVG 20Y
17.36%
CURRENT VS TTM AVG
+5.31%
CURRENT VS 3Y AVG
+4.77%
CURRENT VS 5Y AVG
+7.45%
CURRENT VS 10Y AVG
+13.92%
CURRENT VS 15Y AVG
+21.42%
CURRENT VS 20Y AVG
+34.85%
RMD Competitors' Return on Equity (ROE)
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ResMed Inc. (RMD) | $28.93B | 23.41% | 22.23% | 22.34% | 21.79% |
| Veeva Systems Inc. (VEEV)vs › | $27.84B | 12.89% | 12.42% | 12.32% | 13.45% |
| DexCom, Inc. (DXCM)vs › | $26.76B | 31.47% | 28.93% | 25.01% | 22.95% |
| Biogen Inc. (BIIB)vs › | $31.39B | 7.36% | 8.42% | 11.86% | 16.52% |
| Moderna, Inc. (MRNA)vs › | $26.35B | -43.12% | -32.64% | -13.90% | 0.25% |
| IQVIA Holdings Inc. (IQV)vs › | $31.80B | 22.26% | 21.77% | 21.17% | 17.55% |
| Zoetis Inc. (ZTS)vs › | $32.07B | 81.75% | 66.19% | 56.82% | 52.60% |
| Mettler-Toledo International Inc. (MTD)vs › | $25.44B | -3677.41% | -2178.82% | -341.14% | -117.12% |
| Centene Corp. (CNC)vs › | $32.45B | -30.07% | -10.46% | -1.37% | 1.10% |
| Medline Inc. (MDLN)vs › | $32.87B | 8.55% | 9.02% | 4.86% | 4.86% |
Return Analysis
ROE
23.4%
ROA
17.3%
Return on Equity (ROE) Formula & Definition
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Return on Equity (ROE) FAQ
- What is the return on equity (ROE) for ResMed Inc. (RMD)?
- The return on equity (ROE) for RMD stock is 23.41%.
- Is ResMed Inc.'s return on equity (ROE) high or low?
- The return on equity (ROE) of 23.41% is in line with its 5-year average of 21.79%, near the high end of its 5-year range (16.44%–24.90%).
- What is the TTM average return on equity (ROE) for ResMed Inc. (RMD)?
- The TTM average return on equity (ROE) for RMD stock is 22.23%.
- What is the 3Y average return on equity (ROE) for ResMed Inc. (RMD)?
- The 3Y average return on equity (ROE) for RMD stock is 22.34%.
- What is the 5Y average return on equity (ROE) for ResMed Inc. (RMD)?
- The 5Y average return on equity (ROE) for RMD stock is 21.79%.
- What is the 10Y average return on equity (ROE) for ResMed Inc. (RMD)?
- The 10Y average return on equity (ROE) for RMD stock is 20.55%.
- What is the 15Y average return on equity (ROE) for ResMed Inc. (RMD)?
- The 15Y average return on equity (ROE) for RMD stock is 19.28%.
- What is the 20Y average return on equity (ROE) for ResMed Inc. (RMD)?
- The 20Y average return on equity (ROE) for RMD stock is 17.36%.
RMD Return on Equity (ROE) History
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-06-30 | 23.47% |
| 2024-06-30 | 20.99% |
| 2023-06-30 | 21.73% |
| 2022-06-30 | 23.19% |
| 2021-06-30 | 16.44% |
| 2020-06-30 | 24.90% |
| 2019-06-30 | 19.52% |
| 2018-06-30 | 15.33% |
| 2017-06-30 | 17.46% |
| 2016-06-30 | 20.79% |
| 2015-06-30 | 22.23% |
| 2014-06-30 | 19.64% |
| 2013-06-30 | 19.07% |
| 2012-06-30 | 15.85% |
| 2011-06-30 | 13.11% |
| 2010-06-30 | 14.76% |
| 2009-06-30 | 13.13% |
| 2008-06-30 | 10.20% |
| 2007-06-30 | 7.12% |
| 2006-06-30 | 11.95% |
| 2005-06-30 | 13.67% |
| 2004-06-30 | 15.85% |
| 2003-06-30 | 15.96% |
| 2002-06-30 | 19.44% |
| 2001-06-30 | 11.59% |
| 2000-06-30 | 23.65% |
| 1999-06-30 | 22.49% |
| 1998-06-30 | 20.87% |
| 1997-06-30 | 16.82% |
| 1996-06-30 | 11.54% |
Related Metrics
About ResMed Inc.
ResMed Inc. is a leading global medical technology enterprise engaged in the creation, production, distribution, and marketing of healthcare devices and connected digital solutions. The company operates through two primary segments: Sleep and Respiratory Care, and Software as a Service. Its extensive product range addresses a variety of respiratory disorders, encompassing advanced medical and consumer technologies, ventilation devices, diagnostic equipment, mask systems for both clinical and personal use, headgear, and related accessories, alongside dental devices. ResMed also provides sophisticated cloud-based informatics to enhance patient management and operational efficiency. Notable software offerings in its respiratory portfolio include AirView, for remote device monitoring and setting adjustments; myAir, a personalized application designed to support sleep apnea patients with education and troubleshooting for better engagement and adherence; and U-Sleep, a compliance tracking platform for home medical equipment providers. Complementing these are connectivity modules and Propeller solutions. Furthermore, ResMed offers a robust suite of out-of-hospital software. This includes Brightree, a business management platform for various home care service providers (e.g., HME, pharmacy, infusion, orthotics, prosthetics); MatrixCare, providing care management for senior living, skilled nursing, and hospice organizations; and HEALTHCAREfirst, which supplies electronic health records, billing, coding services, and analytics for home health and hospice agencies. ResMed distributes its offerings primarily to sleep clinics, home healthcare dealers, and hospitals via a global network of distributors and a direct sales force, serving approximately 140 countries. Founded in 1989, the company's headquarters are located in San Diego, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Michael J. Farrell